Agomab Therapeutics

📍 Ghent, Belgium🗓 Founded 2017👥 39 employees💰 Last funded Feb 2021
Biotechnology Research🌐 agomab.com
Website LinkedIn
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Agomab Therapeutics?
Agomab Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did Agomab Therapeutics last raise funding?
The most recent investment in Agomab Therapeutics recorded on gritt.io was in February 2021.
When was Agomab Therapeutics founded?
Agomab Therapeutics was founded in 2017.
What industry is Agomab Therapeutics in?
Agomab Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Agomab Therapeutics based?
Agomab Therapeutics is headquartered in Ghent, Belgium.